Alzamend Neuro (ALZN) Institutional Ownership → Things Are Not Normal in America – Here’s What to Do (From Stansberry Research) (Ad) Free ALZN Stock Alerts $0.52 -0.01 (-1.55%) (As of 10:04 AM ET) Add Compare Share Share OwnershipStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Alzamend Neuro (NASDAQ:ALZN)CurrentInstitutional OwnershipPercentage49.61%Number ofInstitutional Buyers(last 12 months)0Number ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$1.92M Get ALZN Insider Trade Alerts Want to know when executives and insiders are buying or selling Alzamend Neuro stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ALZN Institutional Buying and Selling by Quarter Ad Stansberry ResearchThings Are Not Normal in America – Here’s What to DoGet Out of the Dollar Before May 15 A Wall Street legend and our friend has just warned 896,000 Americans to prepare for May 15.This could be your solution. Alzamend Neuro Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/2/2024Truist Financial Corp154,327$137K0.0%-93.3%2.168% 5/11/2022 RFG Advisory LLC250,000$308K0.0%N/A0.277% 5/9/2022Qube Research & Technologies Ltd78,465$97K0.0%N/A0.087% 4/22/2022Truist Financial Corp2,314,907$2.85M0.0%N/A2.569% 1/31/2022Commonwealth Equity Services LLC116,666$221K0.0%N/A0.131% 11/16/2021Schonfeld Strategic Advisors LLC31,600$97K0.0%N/A0.036% 11/16/2021Two Sigma Investments LP172,913$533K0.0%N/A0.199% 11/16/2021 Warberg Asset Management LLC14,000$43K0.0%N/A0.016% 11/15/2021Sassicaia Capital Advisers LLC93,762$289K0.8%N/A0.108% 9/17/2021Virtu Financial LLC15,402$135K0.0%N/A0.018% 8/16/2021Cubist Systematic Strategies LLC23,672$207K0.0%N/A0.028% 8/13/2021Geode Capital Management LLC44,600$389K0.0%N/A0.052% 8/11/2021Susquehanna International Group LLP57,030$498K0.0%N/A0.067% (Data available from 1/1/2016 forward) ALZN Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ALZN shares? During the previous two years, the following institutional investors and hedge funds held shares of Alzamend Neuro shares: RFG Advisory LLC ($308K), and Truist Financial Corp ($137K), Qube Research & Technologies Ltd ($97K).Learn more on ALZN's institutional investors. What percentage of Alzamend Neuro stock is owned by institutional investors? 49.61% of Alzamend Neuro stock is owned by institutional investors. Learn more on ALZN's institutional investor holdings. Which institutional investors have been buying Alzamend Neuro stock? The following institutional investors have purchased Alzamend Neuro stock in the last 24 months: RFG Advisory LLC ($250K), and Qube Research & Technologies Ltd ($78.47K). How much institutional buying is happening at Alzamend Neuro? Institutional investors have bought a total of 328,465 shares in the last 24 months. This purchase volume represents approximately $6.06M in transactions. Which Alzamend Neuro major shareholders have been selling company stock? The following institutional investors have sold Alzamend Neuro stock in the last 24 months: Truist Financial Corp ($2.16M). How much institutional selling is happening at Alzamend Neuro? Institutional investors have sold a total of 2,160,580 shares in the last 24 months. This volume of shares sold represents approximately $1.92M in transactions. Related Companies: Cingulate Institutional Ownership NexImmune Institutional Ownership Petros Pharmaceuticals Institutional Ownership Exicure Institutional Ownership Bright Minds Biosciences Institutional Ownership Sonnet BioTherapeutics Institutional Ownership Ensysce Biosciences Institutional Ownership Genprex Institutional Ownership Kazia Therapeutics Institutional Ownership Longeveron Institutional Ownership This page (NASDAQ:ALZN) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThis 1 Biotech Stock has been shocking the marketsHuge AlertsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
